Publications by authors named "P Barakat"
ASO Visual Abstract: Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): Cancer Survivors' Perspective Through in-Depth Interviews.
Ann Surg Oncol
January 2025
Article Synopsis
- Castleman disease (CD) is a rare illness characterized by lymphoproliferation, with forms that can affect single or multiple lymph nodes, and is often seen in patients with HIV and related to human herpes virus-8 (HHV-8).
- A case study describes a 68-year-old woman with diabetes and mixed connective tissue disease (MCTD), who presented with symptoms like lymphadenopathy and was diagnosed with the plasma cell subtype of multicentric CD, highlighting the link between CD and systemic conditions.
- Initial treatment resolved her symptoms, but she relapsed years later; this case emphasizes the need for personalized treatment approaches and suggests further studies on the relationship between CD and MCTD are warranted.
Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): Cancer Survivors' Perspective Through In-Depth Interviews.
Ann Surg Oncol
October 2024
Background: CRS/HIPEC patients face unique quality of life (QoL) challenges due to advanced disease (peritoneal carcinomatosis), the extent of procedure, and risk for long-term complications. Standard QoL questionnaires are generic, focusing on tumor type and standard treatments, and likely do not capture this select population's full experience, suggesting the need for tailored instruments. We aimed to characterize the QoL challenges faced by CRS/HIPEC cancer survivors and determine whether these were captured by a standard QoL questionnaire.
View Article and Find Full Text PDFObjectives: There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an effective treatment for PM of non-gynecologic origin and, recently, epithelial ovarian cancer.
View Article and Find Full Text PDFBackground: Most patients with epithelial ovarian cancer (EOC) present with significant peritoneal spread. We assessed collaborative efforts of surgical and gynecological oncologists with expertise in cytoreductive surgery (CRS) in the management of advanced EOC.
Methods: Using a prospective single-center database (2014-2022), we described the operative and oncologic outcomes of stage IIIC-IVA primary and recurrent EOC perioperatively managed jointly by gynecological and surgical oncologists both specializing in CRS and presented components of this collaboration.